+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Next-Generation Cancer Diagnostics Market - Global Forecast 2026-2032- Product Image
Next-Generation Cancer Diagnostics Market - Global Forecast 2026-2032- Product Image
Sale

Next-Generation Cancer Diagnostics Market - Global Forecast 2026-2032

  • Report

  • 186 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5311174
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Next-Generation Cancer Diagnostics Market is projected to reach USD 19.50 Billion in 2026. It is expected to continue growing at a CAGR of 11.26%, reaching USD 37.05 Billion by 2032.

Next-generation cancer diagnostics are redefining oncology by moving detection, tumor classification, therapy selection, and recurrence monitoring closer to real-time clinical decision-making. The field spans liquid biopsy, next-generation sequencing (NGS), digital pathology, multiplex immunohistochemistry, minimal residual disease (MRD) testing, companion diagnostics, and AI-enabled interpretation. Demand is supported by a clear disease burden: the International Agency for Research on Cancer reported about 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, with new cancer cases projected to exceed 35 million by 2050.

For diagnostic developers and advanced laboratory networks, leadership increasingly depends on analytical validity, clinical utility, reimbursement evidence, and scalable data infrastructure. Oncology stakeholders are prioritizing tests that can shorten diagnostic odysseys, identify actionable biomarkers, guide targeted therapy, and support longitudinal monitoring without overburdening clinicians or health systems.

Transformative Shifts in the Diagnostic Landscape

The cancer diagnostics landscape is shifting from single-analyte, tissue-dependent testing toward integrated multi-omic and longitudinal models. Liquid biopsy is gaining relevance for patients with limited tissue availability, while comprehensive genomic profiling is increasingly used to identify rare but actionable alterations across tumor types. Digital pathology is also moving from workflow digitization to computational assessment of morphology, immune contexture, and biomarker expression.

Regulation and evidence expectations are rising in parallel. The European Union In Vitro Diagnostic Regulation has tightened requirements for clinical evidence and post-market surveillance, while the U.S. FDA’s 2024 final rule on laboratory-developed tests signals greater oversight of high-complexity diagnostics. These shifts favor organizations that can combine assay innovation with quality systems, clinical validation, cybersecurity, and transparent performance reporting.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across the cancer diagnostics value chain rather than a single point solution. In pathology, AI can support slide triage, mitosis detection, tumor segmentation, and quantitative biomarker assessment. In genomics, machine learning helps classify variants, prioritize molecular findings, and integrate genomic results with clinical phenotypes. In imaging and radiomics, AI can assist lesion detection, risk stratification, and treatment response assessment when appropriately validated.

The impact is strongest when AI is embedded into governed workflows with human oversight. Diagnostic leaders must address model drift, bias, data provenance, explainability, and interoperability with laboratory information systems and electronic health records. Regulatory-grade AI will depend on diverse training datasets, prospective validation, continuous performance monitoring, and compliance with privacy requirements such as HIPAA and GDPR.

Key Regional Insights Across Major Markets

Asia-Pacific is one of the most dynamic regions for next-generation cancer diagnostics, supported by high cancer incidence, expanding sequencing capacity, and national precision medicine programs in China, Japan, South Korea, Australia, and India. China and India present large-volume adoption opportunities but require localization strategies around affordability, reimbursement, hospital access, and regulatory pathways. Japan, South Korea, and Australia are more mature in genomic oncology adoption, quality accreditation, clinical guideline integration, and research-linked implementation.

North America remains a global innovation hub due to advanced oncology networks, FDA-authorized diagnostics, payer activity, clinical trial infrastructure, and strong biopharma investment. Europe is shaped by EU IVDR implementation, national health technology assessment, cancer screening programs, and data protection rules that influence commercialization and evidence requirements. Latin America, the Middle East, and Africa show growing demand for earlier cancer detection and precision oncology, but adoption is uneven due to infrastructure gaps, specialist shortages, laboratory concentration in major cities, and variable reimbursement coverage.

Key Group Insights Shaping Adoption

ASEAN markets are expanding access to oncology testing through public-private hospital investment, regional reference laboratories, medical tourism hubs, and cross-border testing models, though affordability and out-of-pocket spending remain major determinants of uptake. The GCC is investing in genomic medicine, tertiary cancer centers, population health programs, and digital health infrastructure, creating opportunities for high-value molecular diagnostics aligned with national health transformation agendas. The European Union is important for standardized quality expectations, cross-border regulatory harmonization, and evidence-based adoption, but compliance with IVDR and GDPR raises the bar for market entry.

BRICS countries represent scale, local manufacturing potential, and increasing demand for cost-effective precision oncology across diverse healthcare systems. G7 markets provide the strongest evidence, reimbursement, regulatory, and clinical guideline benchmarks for premium diagnostic platforms. NATO markets overlap heavily with high-income healthcare systems where cybersecurity, supply chain resilience, laboratory continuity, and trusted data exchange are increasingly relevant to laboratory modernization, digital pathology, and AI-enabled diagnostics.

Key Country Insights for Precision Oncology

The United States leads in clinical trial density, companion diagnostic development, digital pathology adoption, and commercialization of advanced oncology testing, although payer coverage and evidence requirements remain decisive. Canada emphasizes publicly funded evaluation, provincial reimbursement decisions, and equitable access, while Mexico and Brazil show rising demand through private oncology networks and expanding molecular testing capacity. In Europe, the United Kingdom, Germany, France, Italy, and Spain are influenced by national reimbursement pathways, cancer plans, biomarker testing guidelines, and centralized or regional laboratory models, while Russia faces access, import, and supply constraints that can affect availability of advanced molecular platforms.

In Asia-Pacific, China is scaling domestic sequencing, oncology innovation, and hospital-based molecular testing; India is expanding affordable diagnostics across a large patient base with growing use of NGS and liquid biopsy in metropolitan centers; and Japan supports mature precision oncology pathways through regulated genomic profiling and strong clinical adoption in specialized centers. South Korea combines digital health strength with advanced hospital systems and high oncology research intensity, while Australia benefits from robust research networks, cancer registries, public health infrastructure, and quality-led implementation of genomic testing.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically actionable indications where next-generation cancer diagnostics can demonstrate measurable impact on treatment selection, time to diagnosis, trial enrollment, or recurrence monitoring. Evidence packages should include analytical performance, clinical validity, clinical utility, health-economic value, and real-world outcomes across diverse populations. Partnerships with cancer centers, pathology networks, biopharma organizations, and payers can accelerate adoption when evidence generation is built into deployment.

Operationally, organizations should invest in interoperable platforms, sample logistics, laboratory automation, quality management systems, and secure data governance. AI-enabled diagnostics require prospective validation, bias testing, workflow integration, model monitoring, and clear clinician-facing outputs. Regional commercialization should be tailored to reimbursement maturity, regulatory expectations, data privacy rules, and local testing infrastructure rather than relying on a single global launch model.

Research Methodology

A robust research methodology for next-generation cancer diagnostics combines secondary intelligence, primary validation, and structured evidence synthesis. Secondary research should include peer-reviewed literature, clinical guidelines, regulatory databases, cancer registry data, reimbursement decisions, patent activity, and public health datasets from organizations such as WHO, IARC, FDA, EMA, CDC, and national oncology agencies.

Primary research should validate adoption barriers, pricing dynamics, test utilization, workflow needs, and procurement priorities through interviews with oncologists, pathologists, molecular laboratory directors, payers, regulatory specialists, and industry executives. Findings should be triangulated across test utilization patterns, installed laboratory capacity, cancer incidence and prevalence patterns, biomarker eligibility, reimbursement status, regulatory pathways, and competitive positioning, with assumptions reviewed for regional variance and data reliability.

Conclusion

Next-generation cancer diagnostics are becoming central to precision oncology, enabling earlier detection, more accurate tumor characterization, targeted therapy selection, and longitudinal disease monitoring. The strongest opportunities will favor organizations that unite scientific credibility, scalable laboratory operations, regulatory readiness, payer-aligned evidence, and secure data infrastructure.

As cancer incidence rises globally, the industry will increasingly reward diagnostics that are actionable, affordable, reproducible, and integrated into clinical workflows. Organizations that combine multi-omic innovation with AI governance, regional commercialization discipline, and real-world evidence generation will be best positioned to shape the future of cancer care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Next-Generation Cancer Diagnostics Market, by Product
7.1. Introduction
7.2. Instruments
7.2.1. Analyzers
7.2.2. Sequencers
7.3. Reagents & Consumables
7.4. Software & Services
8. Next-Generation Cancer Diagnostics Market, by Technology
8.1. Introduction
8.2. DNA Microarrays
8.3. Lab-on- a- chip & Reverse Transcriptase-PCR
8.4. Next-generation Sequencing
8.5. Protein Microarrays
8.6. qPCR & Multiplexing
9. Next-Generation Cancer Diagnostics Market, by Cancer Type
9.1. Introduction
9.2. Breast Cancer
9.3. Colorectal Cancer
9.4. Lung Cancer
9.5. Prostate Cancer
10. Next-Generation Cancer Diagnostics Market, by Sample Type
10.1. Introduction
10.2. Blood-Based Samples
10.3. Tissue Biopsy
11. Next-Generation Cancer Diagnostics Market, by Application
11.1. Introduction
11.2. Cancer Screening
11.3. Companion Diagnostics
11.4. Prognostics
11.5. Risk Assessment
11.6. Therapeutic Monitoring
12. Next-Generation Cancer Diagnostics Market, by Region
12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East
13. Next-Generation Cancer Diagnostics Market, by Group
13.1. NATO
13.2. G7
13.3. BRICS
13.4. European Union
13.5. ASEAN
13.6. GCC
14. Next-Generation Cancer Diagnostics Market, by Country
14.1. China
14.2. United States
14.3. Japan
14.4. India
14.5. Germany
14.6. United Kingdom
14.7. Australia
14.8. France
14.9. South Korea
14.10. Italy
14.11. Canada
14.12. Russia
14.13. Brazil
14.14. Mexico
14.15. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Abbott Laboratories
16.2. Adaptive Biotechnologies Corporation
16.3. Agena Bioscience, Inc. by Mesa Laboratories, Inc.
16.4. Agilent Technologies, Inc.
16.5. Akadeum Life Sciences
16.6. Almac Group
16.7. Becton, Dickinson & Company
16.8. Bio-Techne Corporation
16.9. Biological Dynamics Inc.
16.10. BioNTech SE
16.11. Castle Biosciences Inc.
16.12. Danaher Corporation
16.13. Exact Sciences Corporation
16.14. F. Hoffmann-La Roche Ltd.
16.15. GE HealthCare
16.16. Hologic Inc.
16.17. Illumina, Inc.
16.18. Johnson & Johnson Services, Inc.
16.19. Konica Minolta, Inc.
16.20. Koninklijke Philips N.V.
16.21. NeoGenomics Laboratories
16.22. Novartis AG
16.23. OPKO Health, Inc.
16.24. Oxford Nanopore Technologies Limited
16.25. Qiagen N.V.
16.26. Revvity, Inc.
16.27. Siemens Healthineers AG
16.28. Sysmex Corporation
16.29. Telerad Tech
16.30. Thermo Fisher Scientific, Inc.
List of Figures
FIGURE 1. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025 VS 2032 (%)
FIGURE 7. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 9. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL ANALYZERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL ANALYZERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL ANALYZERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL SEQUENCERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL SEQUENCERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL SEQUENCERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL REAGENTS & CONSUMABLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL REAGENTS & CONSUMABLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL REAGENTS & CONSUMABLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL DNA MICROARRAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL DNA MICROARRAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL DNA MICROARRAYS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL LAB-ON- A- CHIP & REVERSE TRANSCRIPTASE-PCR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL LAB-ON- A- CHIP & REVERSE TRANSCRIPTASE-PCR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL LAB-ON- A- CHIP & REVERSE TRANSCRIPTASE-PCR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL PROTEIN MICROARRAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL PROTEIN MICROARRAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL PROTEIN MICROARRAYS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL QPCR & MULTIPLEXING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL QPCR & MULTIPLEXING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL QPCR & MULTIPLEXING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL BLOOD-BASED SAMPLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL BLOOD-BASED SAMPLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL BLOOD-BASED SAMPLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL TISSUE BIOPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL TISSUE BIOPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL TISSUE BIOPSY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL CANCER SCREENING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL CANCER SCREENING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL CANCER SCREENING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL PROGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL PROGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL PROGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL RISK ASSESSMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL RISK ASSESSMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL RISK ASSESSMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL THERAPEUTIC MONITORING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL THERAPEUTIC MONITORING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL THERAPEUTIC MONITORING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 74. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 75. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 76. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 77. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 78. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 79. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 81. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 82. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 83. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 84. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 85. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 86. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 88. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 89. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 90. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 91. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 92. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 93. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 95. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 96. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 97. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 98. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 99. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 100. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 102. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 103. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 104. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 105. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 106. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 107. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 109. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 110. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 111. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 112. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 113. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 115. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 116. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 117. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 118. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 119. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 120. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 121. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 122. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 123. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 124. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 125. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 126. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 127. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 128. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 129. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 130. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 131. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 132. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 133. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 134. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 135. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 136. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 137. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 138. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 139. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 140. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 141. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 142. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 143. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 144. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 145. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 146. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 147. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 148. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 149. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 150. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 151. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 152. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 153. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 154. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 155. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 156. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 157. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 158. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 159. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 160. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 161. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 162. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 163. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 164. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 165. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 166. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 167. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 168. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 169. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 170. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 171. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 172. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 173. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 174. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 175. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 176. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 177. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 178. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 179. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 180. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 181. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 182. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 183. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 184. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 185. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 186. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 187. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 188. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 189. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 190. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 191. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 192. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 193. UNITED KINGDOM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 194. UNITED KINGDOM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 195. UNITED KINGDOM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 196. UNITED KINGDOM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 197. UNITED KINGDOM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 198. UNITED KINGDOM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 199. UNITED KINGDOM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 200. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 201. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 202. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 203. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 204. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 205. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 206. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 207. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 208. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 209. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 210. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 211. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 212. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 213. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 214. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 215. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 216. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 217. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 218. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 219. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 220. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 221. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 222. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 223. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 224. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 225. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 226. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 227. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 228. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 229. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 230. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 231. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 232. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 233. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 234. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 235. RUSSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 236. RUSSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 237. RUSSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 238. RUSSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 239. RUSSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 240. RUSSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 241. RUSSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 242. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 243. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 244. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 245. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 246. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 247. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 248. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 249. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 250. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 251. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 252. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 253. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 254. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 255. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 256. SPAIN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 257. SPAIN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 258. SPAIN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 259. SPAIN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 260. SPAIN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 261. SPAIN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 262. SPAIN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 263. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 264. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Abbott Laboratories
  • Adaptive Biotechnologies Corporation
  • Agena Bioscience, Inc. by Mesa Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Akadeum Life Sciences
  • Almac Group
  • Becton, Dickinson & Company
  • Bio-Techne Corporation
  • Biological Dynamics Inc.
  • BioNTech SE
  • Castle Biosciences Inc.
  • Danaher Corporation
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • GE HealthCare
  • Hologic Inc.
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc.
  • Konica Minolta, Inc.
  • Koninklijke Philips N.V.
  • NeoGenomics Laboratories
  • Novartis AG
  • OPKO Health, Inc.
  • Oxford Nanopore Technologies Limited
  • Qiagen N.V.
  • Revvity, Inc.
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Telerad Tech
  • Thermo Fisher Scientific, Inc.

Table Information

Report AttributeDetails
No. of Pages186
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 19.5 Billion
Forecasted Market Value ( USD ) by 2032 $ 37.05 Billion
Compound Annual Growth Rate11.2%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Next-Generation Gynecological Cancer Diagnostics Market - Global Forecast 2026-2032 - Product Image

Next-Generation Gynecological Cancer Diagnostics Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Brain Cancer Diagnostics Market - Global Forecast 2026-2032 - Product Image

Brain Cancer Diagnostics Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Next Generation Cancer Diagnostics - Global Strategic Business Report - Product Image

Next Generation Cancer Diagnostics - Global Strategic Business Report

  • Report
  • 175 Pages
  • Global
From
Blood Cancer Diagnostics - Global Strategic Business Report - Product Image

Blood Cancer Diagnostics - Global Strategic Business Report

  • Report
  • 372 Pages
  • Global
From
Next Generation Cancer Diagnostics Market Size, Share & Trends Analysis Report by Technology (Next Generation Sequencing, qPCR & Multiplexing, DNA Microarrays), Application, Cancer Type, Function, and Region with Growth Forecasts, 2025-2033 - Product Image

Next Generation Cancer Diagnostics Market Size, Share & Trends Analysis Report by Technology (Next Generation Sequencing, qPCR & Multiplexing, DNA Microarrays), Application, Cancer Type, Function, and Region with Growth Forecasts, 2025-2033

  • Report
  • 138 Pages
  • Global
From

About the Next Generation Cancer Diagnostics Market

The Next Generation Cancer Diagnostics market is a subset of the Diagnostics industry that focuses on the development of advanced technologies for the early detection and diagnosis of cancer. These technologies include molecular diagnostics, biomarkers, imaging, and other methods that can detect cancer at its earliest stages. This market is driven by the need for more accurate and timely diagnosis of cancer, as well as the increasing prevalence of the disease. The Next Generation Cancer Diagnostics market is expected to grow significantly in the coming years, driven by the increasing demand for early diagnosis and the development of new technologies. This market is also expected to benefit from the increasing availability of data and the development of artificial intelligence and machine learning. Some of the major players in the Next Generation Cancer Diagnostics market include Illumina, Thermo Fisher Scientific, Roche, Qiagen, and Agilent Technologies. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.